文献速递结核与非结核分枝杆菌

印度耐药结核儿童及青少年抗结核药物药代动力学多中心观察研究

Pharmacokinetics of anti-TB drugs in children and adolescents with drug-resistant TB: a multicentre observational study from India.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

在印度项目条件下对200例1-18岁耐药结核儿童及青少年开展多中心观察研究,采用HPLC测定莫西沙星、左氧氟沙星、环丝氨酸、乙硫异烟胺、利福平、异烟肼和吡嗪酰胺的稳态药代动力学。达标峰浓度频率为13%(利福平)至82%(吡嗪酰胺),亚治疗峰浓度和超治疗浓度频率均较高;12岁以下儿童莫西沙星最大浓度和12小时暴露显著低于12岁以上儿童。

要点

  • 利福平达标峰浓度频率仅13%,吡嗪酰胺为82%。
  • 亚治疗峰浓度频率:利福平74%、左氧氟沙星41%、莫西沙星29%。
  • 12岁以下儿童莫西沙星最大浓度和12小时暴露显著低于12岁以上儿童。

核心结论

  • 年龄显著影响莫西沙星的血浆浓度和暴露。
  • 观察到的亚治疗和超治疗浓度频率凸显了在耐药结核儿童和青少年中进行剂量优化和治疗药物监测的必要性。

研究设计与样本

  • 多中心观察研究,纳入印度项目条件下1-18岁耐药结核儿童和青少年200例(中位年龄12岁,IQR 9-14)。
  • 采用HPLC法进行稳态药代动力学评估,包括密集采样89例和稀疏采样111例,测定莫西沙星、左氧氟沙星、环丝氨酸、乙硫异烟胺、利福平、异烟肼和吡嗪酰胺的血浆水平。

主要发现

  • 达标峰浓度频率范围为13%(利福平)至82%(吡嗪酰胺)。
  • 亚治疗峰浓度频率:吡嗪酰胺15%、环丝氨酸19%、莫西沙星29%、左氧氟沙星41%、利福平74%。
  • 超治疗浓度频率范围为3%(吡嗪酰胺)至60%(异烟肼)。
  • 12岁以下年龄组中,莫西沙星的中位血浆最大浓度和12小时暴露显著低于12岁以上年龄组,尽管体重调整剂量相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug-resistant tuberculosis (DR-TB) is one of the challenging forms of TB to treat, not only in adults but also in children and adolescents. Further, there is a void in the treatment strategy exclusively for children due to various reasons, including paucity of pharmacokinetic (PK) data on anti-TB drugs across the globe. In this context, the present study aimed at assessing the PK of some of the anti-TB drugs used in DR-TB treatment regimens. METHOD: A multicentre observational study was conducted among DR-TB children and adolescents (n = 200) aged 1-18 years (median: 12 years; IQR: 9-14) treated under programmatic settings in India. Steady-state PK (intensive: n = 89; and sparse: n = 111) evaluation of moxifloxacin, levofloxacin, cycloserine, ethionamide, rifampicin, isoniazid and pyrazinamide was carried out by measuring plasma levels using HPLC methods. RESULTS: In the study population, the frequency of achieving peak plasma concentrations ranged between 13% (for rifampicin) to 82% (for pyrazinamide), whereas the frequency of suboptimal peak concentration for pyrazinamide, cycloserine, moxifloxacin, levofloxacin and rifampicin was 15%, 19%, 29%, 41% and 74%, respectively. Further, the frequency of supratherapeutic levels among patients varied between 3% for pyrazinamide and 60% for isoniazid. In the below-12 years age category, the median plasma maximum concentration and 12 h exposure of moxifloxacin were significantly lower than that of the above-12 years category despite similar weight-adjusted dosing. CONCLUSIONS: Age significantly impacted the plasma concentration and exposure of moxifloxacin. The observed frequencies of suboptimal and supratherapeutic concentrations underscore the necessity for dose optimization and therapeutic drug monitoring in children and adolescents undergoing DR-TB treatment.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Agibothu Kupparam HK, Shah I, Chandrasekaran P, et al. Pharmacokinetics of anti-TB drugs in children and adolescents with drug-resistant TB: a multicentre observational study from India. J Antimicrob Chemother. 2024. PMID: 39308327. doi:10.1093/jac/dkae311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。